These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 38206289)

  • 1. Systemic Treatment of Patients With Metastatic Breast Cancer: ASCO Resource-Stratified Guideline Q and A.
    Al Sukhun S; Koczwara B; Temin S; Arun BK
    JCO Glob Oncol; 2024 Jan; 10():e2300411. PubMed ID: 38206289
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Guideline on Muscle-Invasive and Metastatic Bladder Cancer (European Association of Urology Guideline): American Society of Clinical Oncology Clinical Practice Guideline Endorsement.
    Milowsky MI; Rumble RB; Booth CM; Gilligan T; Eapen LJ; Hauke RJ; Boumansour P; Lee CT
    J Clin Oncol; 2016 Jun; 34(16):1945-52. PubMed ID: 27001593
    [TBL] [Abstract][Full Text] [Related]  

  • 3. American Society of Clinical Oncology endorsement of the cancer care Ontario practice guideline on adjuvant ovarian ablation in the treatment of premenopausal women with early-stage invasive breast cancer.
    Griggs JJ; Somerfield MR; Anderson H; Henry NL; Hudis CA; Khatcheressian JL; Partridge AH; Prestrud AA; Davidson NE
    J Clin Oncol; 2011 Oct; 29(29):3939-42. PubMed ID: 21900112
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Systemic Treatment of Patients With Metastatic Breast Cancer: ASCO Resource-Stratified Guideline.
    Al Sukhun S; Temin S; Barrios CH; Antone NZ; Guerra YC; Chavez-MacGregor M; Chopra R; Danso MA; Gomez HL; Homian NM; Kandil A; Kithaka B; Koczwara B; Moy B; Nakigudde G; Petracci FE; Rugo HS; El Saghir NS; Arun BK
    JCO Glob Oncol; 2024 Jan; 10():e2300285. PubMed ID: 38206277
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of Patient and Disease Factors in Adjuvant Systemic Therapy Decision Making for Early-Stage, Operable Breast Cancer: Update of the ASCO Endorsement of the Cancer Care Ontario Guideline.
    Henry NL; Somerfield MR; Abramson VG; Ismaila N; Allison KH; Anders CK; Chingos DT; Eisen A; Ferrari BL; Openshaw TH; Spears PA; Vikas P; Stearns V
    J Clin Oncol; 2019 Aug; 37(22):1965-1977. PubMed ID: 31206315
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Systemic therapy of breast cancer: practice guideline].
    Horváth Z; Boér K; Dank M; Kahán Z; Kocsis J; Kövér E; Pajkos G; Pikó B; Rubovszky G; Eckhardt S
    Magy Onkol; 2016 Sep; 60(3):241-57. PubMed ID: 27579723
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Integrative Therapies During and After Breast Cancer Treatment: ASCO Endorsement of the SIO Clinical Practice Guideline.
    Lyman GH; Greenlee H; Bohlke K; Bao T; DeMichele AM; Deng GE; Fouladbakhsh JM; Gil B; Hershman DL; Mansfield S; Mussallem DM; Mustian KM; Price E; Rafte S; Cohen L
    J Clin Oncol; 2018 Sep; 36(25):2647-2655. PubMed ID: 29889605
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metastatic Pancreatic Cancer: ASCO Clinical Practice Guideline Update.
    Sohal DPS; Kennedy EB; Khorana A; Copur MS; Crane CH; Garrido-Laguna I; Krishnamurthi S; Moravek C; O'Reilly EM; Philip PA; Ramanathan RK; Ruggiero JT; Shah MA; Urba S; Uronis HE; Lau MW; Laheru D
    J Clin Oncol; 2018 Aug; 36(24):2545-2556. PubMed ID: 29791286
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of Patient and Disease Factors in Adjuvant Systemic Therapy Decision Making for Early-Stage, Operable Breast Cancer: American Society of Clinical Oncology Endorsement of Cancer Care Ontario Guideline Recommendations.
    Henry NL; Somerfield MR; Abramson VG; Allison KH; Anders CK; Chingos DT; Hurria A; Openshaw TH; Krop IE
    J Clin Oncol; 2016 Jul; 34(19):2303-11. PubMed ID: 27001586
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adherence to surveillance care guidelines after breast and colorectal cancer treatment with curative intent.
    Salloum RG; Hornbrook MC; Fishman PA; Ritzwoller DP; O'Keeffe Rossetti MC; Elston Lafata J
    Cancer; 2012 Nov; 118(22):5644-51. PubMed ID: 22434568
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of the updated 2018 ASCO/CAP guidelines on HER2 FISH testing in invasive breast cancer: a retrospective study of HER2 fish results of 2233 cases.
    Liu ZH; Wang K; Lin DY; Xu J; Chen J; Long XY; Ge Y; Luo XL; Zhang KP; Liu YH; Xu FP
    Breast Cancer Res Treat; 2019 May; 175(1):51-57. PubMed ID: 30712197
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Margins for breast-conserving surgery with whole-breast irradiation in stage I and II invasive breast cancer: American Society of Clinical Oncology endorsement of the Society of Surgical Oncology/American Society for Radiation Oncology consensus guideline.
    Buchholz TA; Somerfield MR; Griggs JJ; El-Eid S; Hammond ME; Lyman GH; Mason G; Newman LA
    J Clin Oncol; 2014 May; 32(14):1502-6. PubMed ID: 24711553
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Integrative Therapies During and After Breast Cancer Treatment: ASCO Endorsement of the SIO Clinical Practice Guideline Summary.
    Lyman GH; Bohlke K; Cohen L
    J Oncol Pract; 2018 Aug; 14(8):495-499. PubMed ID: 30096271
    [No Abstract]   [Full Text] [Related]  

  • 14. Guideline-Concordant Treatment Among Elderly Women With HER2-Positive Metastatic Breast Cancer in the United States.
    Vyas AM; Aroke H; Kogut S
    J Natl Compr Canc Netw; 2020 Apr; 18(4):405-413. PubMed ID: 32259787
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Endocrine Treatment and Targeted Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: ASCO Guideline Update.
    Burstein HJ; Somerfield MR; Barton DL; Dorris A; Fallowfield LJ; Jain D; Johnston SRD; Korde LA; Litton JK; Macrae ER; Peterson LL; Vikas P; Yung RL; Rugo HS
    J Clin Oncol; 2021 Dec; 39(35):3959-3977. PubMed ID: 34324367
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of Adjuvant Bisphosphonates and Other Bone-Modifying Agents in Breast Cancer: ASCO-OH (CCO) Guideline Update.
    Eisen A; Somerfield MR; Accordino MK; Blanchette PS; Clemons MJ; Dhesy-Thind S; Dillmon MS; D'Oronzo S; Fletcher GG; Frank ES; Hallmeyer S; Makhoul I; Moy B; Thawer A; Wu JY; Van Poznak CH
    J Clin Oncol; 2022 Mar; 40(7):787-800. PubMed ID: 35041467
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recommendations on Disease Management for Patients With Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases: ASCO Clinical Practice Guideline Update.
    Ramakrishna N; Temin S; Chandarlapaty S; Crews JR; Davidson NE; Esteva FJ; Giordano SH; Kirshner JJ; Krop IE; Levinson J; Modi S; Patt DA; Perlmutter J; Winer EP; Lin NU
    J Clin Oncol; 2018 Sep; 36(27):2804-2807. PubMed ID: 29939840
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Application of the 2013 ASCO/CAP guideline and the SISH technique for HER2 testing of breast cancer selects more patients for anti-HER2 treatment.
    Polónia A; Leitão D; Schmitt F
    Virchows Arch; 2016 Apr; 468(4):417-23. PubMed ID: 26754674
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Supportive and palliative care for metastatic breast cancer: resource allocations in low- and middle-income countries. A Breast Health Global Initiative 2013 consensus statement.
    Cleary J; Ddungu H; Distelhorst SR; Ripamonti C; Rodin GM; Bushnaq MA; Clegg-Lamptey JN; Connor SR; Diwani MB; Eniu A; Harford JB; Kumar S; Rajagopal MR; Thompson B; Gralow JR; Anderson BO
    Breast; 2013 Oct; 22(5):616-27. PubMed ID: 23972474
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HER2 Testing for Breast Cancer in the Genomics Laboratory: A Sea Change for Fluorescence In Situ Hybridization.
    Geiersbach KB; Sill DR; Meyer RG; Yuhas JA; Sukov WR; Mounajjed T; Carter JM; Jenkins RB; Chen B
    Arch Pathol Lab Med; 2021 Jul; 145(7):883-886. PubMed ID: 33112955
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.